In another study, causal inference testing and Mendelian randomisation demonstrated that HLA genetic variants mediate risk for MS via methylation changes in a DMR within HLA-DRB1, leading to changes in HLA-DRB1 expression [75]. The gene discussed is HLA-DRB1; the disease is myeloid sarcoma.